Zobrazeno 1 - 10
of 500
pro vyhledávání: '"J Lokich"'
Publikováno v:
Scandinavian Journal of Immunology. 19:193-198
Two hundred and seventy-seven patients with a broad spectrum of neoplastic diseases, including 10 classes of solid tumours and three classes of haematologic malignancies, were retrospectively surveyed, and from the same sample of plasma or serum thei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd172a5839dc754994e31cfdd58b725
https://doi.org/10.1111/j.1365-3083.1984.tb00919.x
https://doi.org/10.1111/j.1365-3083.1984.tb00919.x
Autor:
Jacob J. Lokich
Publikováno v:
American Journal of Clinical Oncology. 24:336-340
Combining antineoplastic analogues may increase efficacy by increasing the serum and intracellular concentration of the cytotoxic moiety shared by the analogues. Topotecan and irinotecan are two camptothecan analogues that are active in different hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31627248eee00c685df4131232b63080
https://doi.org/10.1097/00000421-200108000-00003
https://doi.org/10.1097/00000421-200108000-00003
Autor:
Jacob J. Lokich
Publikováno v:
Cancer Investigation. 19:756-760
The choice between cisplatin (cis) and carboplatin (carbo) as the platinum analogue to be used in combination chemotherapy regimens continues to be a point of controversy, and a new platinum analog...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a44399c340d66144ffd8b4edf70894
https://doi.org/10.1081/cnv-100106152
https://doi.org/10.1081/cnv-100106152
Autor:
Jacob J. Lokich
Publikováno v:
Cancer Investigation. 19:854-857
The recent introduction of three oral fluoropyrimidine preparations to the antineoplastic armamentarium has been welcomed as a major step forward in providing a patient-convenient delivery system f...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7f8e4f00eb4b8ddcd8a6fbcd495b1ed
https://doi.org/10.1081/cnv-100107747
https://doi.org/10.1081/cnv-100107747
Autor:
Norwood R. Anderson, Frank V. Coco, Murray M. Bern, Edward Dow, Peter Oliynyk, Jacob J. Lokich, Henry Sonneborn
Publikováno v:
Cancer. 85:2347-2351
BACKGROUND Paclitaxel (T), etoposide (E), and cisplatin (P) are each active in gastric carcinoma, either as single agents or as part of a multidrug regimen. To the authors' knowledge, the combination of these three agents in the treatment of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40d7e6793c869dbed834bf71ec584e47
https://doi.org/10.1002/(sici)1097-0142(19990601)85:11<2347::aid-cncr8>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19990601)85:11<2347::aid-cncr8>3.0.co
Publikováno v:
Cancer. 85:499-503
BACKGROUND Paclitaxel, cisplatin, and vinorelbine are three important antineoplastic drugs with different mechanisms of cell kill. A combination of these three drugs potentially could have additive therapeutic effects. METHODS The three-drug combinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01dc234ec3940054654b951e84ecf65c
https://doi.org/10.1002/(sici)1097-0142(19990115)85:2<499::aid-cncr31>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19990115)85:2<499::aid-cncr31>3.0.co
Autor:
Jacob J. Lokich
Publikováno v:
Cancer Investigation. 17:547-550
Multifractionated dosing (MFD) schedules for chemotherapy administration such as weekly or twice weekly administration are intended to maximize dose intensity while minimizing toxicity, but the cumulative drug effect may result in neutropenia necessi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b397c78312ce5c543f36ae4957c256c
https://doi.org/10.3109/07357909909032865
https://doi.org/10.3109/07357909909032865
Autor:
Marc Buyse, E. Quinaux, Jacqueline Benedetti, B Weinerman, Agnès Laplanche, J Fryer, R Hansen, John S. Macdonald, G Brufman, E Levy, Louise Ryan, Cynthia G. Leichman, J Pater, Pascal Piedbois, R Isacson, J.P. Pignon, Ph. Rougier, J Lokich, Pierre Thirion, Benny Zee
Publikováno v:
Journal of Clinical Oncology. 16:3537-3541
PURPOSE Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::211eac9df79209217c8e39d64c9f668b
https://doi.org/10.1200/jco.1998.16.11.3537
https://doi.org/10.1200/jco.1998.16.11.3537
Publikováno v:
European Journal of Cancer. 34:664-667
66 patients with a variety of tumour types received the multifractionated TPE three drug regimen in a non-random allocation as a 5 day schedule (schedule A) or as a twice weekly schedule (schedule B). The dose per fraction for each component drug was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b20aa0c7620317ad5d7c4683bc842890
https://doi.org/10.1016/s0959-8049(97)10108-3
https://doi.org/10.1016/s0959-8049(97)10108-3
Publikováno v:
European Journal of Cancer. 34:659-663
In this phase II study, paclitaxel was added to the combination of cisplatin and etoposide (TPE regimen), in 37 patients with advanced non-small cell lung cancer, using a multifractionated dosing schedule. The total dose of paclitaxel (175-200 mg/m2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f62e690e3b43fd92f1204f130ec9b744
https://doi.org/10.1016/s0959-8049(97)10104-6
https://doi.org/10.1016/s0959-8049(97)10104-6